A Phase 4 interventional study of Naproxen Sodium (Aleve, BAY117031) and Hydrocodone/Acetaminophen in Pain, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-07-14.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing naproxen in Pain — 1 open to participants now, 2 under way, none of them phase 3. Naproxen · Pain.
Among the 25 studies testing naproxen in Pain, this one is the 9th largest by enrollment, is the only one that started in 2020, is one of 9 in phase 4, and was the 19th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →1 of the 25 studies testing naproxen in Pain is open now, in 1 country. Recruiting first, the newest first:
American University of Beirut Medical Center · Sites in Lebanon
Ages 18+
By country, each count listing its studies:
Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 384 (41%) set no upper age limit and 432 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 221 is above the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 100 across the 25 interventional studies. Of the 22 that completed or were terminated, 13 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 25 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
14 studies in Pain by Bayer: none open now, none under way, none of them phase 3. Of 14 finished, 5 (36%) have results posted.
Among the 14 studies in Pain by Bayer, this one is the 6th largest by enrollment, is one of 2 that started in 2020, is the only one in phase 4, and was the 12th registered.
Bayer’s Pain studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing naproxen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 14 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
With this study researchers want to collect information on how long the pain relief lasts after a fixed dose of naproxen sodium or hydrocodone/acetaminophen or placebo (contains no medication) over 12 hours in subjects experiencing moderate to severe pain after having their wisdom teeth removed. Naproxen Sodium (Aleve®) is a drug that is used for the temporary relief of minor aches and pains.
Hydrocodone/Acetaminophen is a combination drug used to relieve moderate to severe pain. It contains an opioid (narcotic) pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects will undergo surgical extraction of three or four third molars, two of which must be mandibular molars. Maxillary third molars may be removed regardless of impaction level. The mandibular extractions must have a trauma rating of mild or moderate and meet one of the following scenarios:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
Drug: Naproxen Sodium (Aleve, BAY117031)
After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
Drug: Hydrocodone/Acetaminophen
After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
Drug: Placebo
220 mg per tablet, two tablets (440 mg), intake a single dose orally.
5/325 mg per tablet, two tablets (10/650 mg), intake a single dose orally.
two tablets, intake a single dose orally.
Sum of Pain Intensity Difference Over 12 Hours (SPID 0-12)
Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference is indicative of improvement. Sum of Pain Intensity Differences (SPIDs) was calculated by multiplying the PID score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. SPID over 12 hours ranges from -120 to 120. A higher value indicates a better pain reduction.
Time frame: Up to 12 hours postdose
Total Pain Relief Over 12 Hours (TOTPAR 0-12)
Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. TOTPAR over 12 hours ranges from 0 to 48, a higher value indicates more pain relief.
Time frame: Up to 12 hours postdose
Total Pain Relief Over 6 Hours (TOTPAR 0-6)
Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. TOTPAR over 6 hours ranges from 0 to 24, a higher value indicates more pain relief.
Time frame: Up to 6 hours postdose
Sum of Pain Intensity Difference Over 6 Hours (SPID 0-6)
Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference is indicative of improvement. Sum of Pain Intensity Differences (SPIDs) was calculated by multiplying the PID score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. SPID over 6 hours ranges from -60 to 60. A higher value indicates a better pain reduction.
Time frame: Up to 6 hours postdose
Number of Participants Required or Did Not Reqiure Rescue Pain Medication
Time frame: Up to 12 hours postdose
Amount of Rescue Medication
To quantify the use of opioid analgesics in treatment of post-operative dental pain, the amount of rescue medications (opioids) was converted to a standard unit, which was Morphine Milligram Equivalent (MME) using below formula: MME/Day = Strength per Unit × (Number of units / Days supply) × MME conversion factor
Time frame: Up to 12 hours postdose
Time to First Use of Rescue Medication
If a subject did not take the rescue medication during the treatment period, (s)he was censored at the time of last assessment.
Time frame: Up to 12 hours postdose
Duration of Pain at Least Half Gone Over 12 Hours
Time frame: Up to 12 hours postdose
Duration of Pain at Least Half Gone Over 6 Hours
Time frame: Up to 6 hours postdose
Study was conducted at one center in the US between 12-MAR-2020 (first participant first visit) and 05-OCT-2020 (last participant last visit).
| Milestone | Naproxen Sodium | Hydrocodone / APAP | Placebo |
|---|---|---|---|
| Started | 90 | 87 | 44 |
| Completed | 85 | 84 | 42 |
| Not completed | 5 | 3 | 2 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 3 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 |
Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference is indicative of improvement. Sum of Pain Intensity Differences (SPIDs) was calculated by multiplying the PID score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. SPID over 12 hours ranges from -120 to 120. A higher value indicates a better pain reduction.
| Scores on a scale*hours | Naproxen Sodium | Hydrocodone / APAP | Placebo |
|---|---|---|---|
| Sum of Pain Intensity Difference Over 12 Hours (SPID 0-12) | 53.20 ± 3.09 | 38.39 ± 3.14 | 13.57 ± 4.35 |
Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. TOTPAR over 12 hours ranges from 0 to 48, a higher value indicates more pain relief.
| Scores on a scale*hours | Naproxen Sodium | Hydrocodone / APAP | Placebo |
|---|---|---|---|
| Total Pain Relief Over 12 Hours (TOTPAR 0-12) | 28.41 ± 1.36 | 21.31 ± 1.39 | 10.63 ± 1.92 |
Pain relief is measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief). Total Pain Relief is calculated as the area under the curve of pain relief score over time for the given time period by multiplying the pain relief score at each time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. TOTPAR over 6 hours ranges from 0 to 24, a higher value indicates more pain relief.
| Scores on a scale*hours | Naproxen Sodium | Hydrocodone / APAP | Placebo |
|---|---|---|---|
| Total Pain Relief Over 6 Hours (TOTPAR 0-6) | 14.53 ± 0.61 | 12.69 ± 0.62 | 5.14 ± 0.87 |
Pain intensity is measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each post dose time point, pain intensity difference (PID) is derived by subtracting the pain intensity at the post dose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference is indicative of improvement. Sum of Pain Intensity Differences (SPIDs) was calculated by multiplying the PID score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values over the specific time period. SPID over 6 hours ranges from -60 to 60. A higher value indicates a better pain reduction.
| Scores on a scale*hours | Naproxen Sodium | Hydrocodone / APAP | Placebo |
|---|---|---|---|
| Sum of Pain Intensity Difference Over 6 Hours (SPID 0-6) | 28.41 ± 1.46 | 24.35 ± 1.48 | 6.23 ± 2.05 |
| Participants | Naproxen Sodium | Hydrocodone / APAP | Placebo |
|---|---|---|---|
| Number of participants required rescue pain medication | 18 | 43 | 29 |
| Number of participants did not require any rescue pain medication | 68 | 40 | 14 |
To quantify the use of opioid analgesics in treatment of post-operative dental pain, the amount of rescue medications (opioids) was converted to a standard unit, which was Morphine Milligram Equivalent (MME) using below formula: MME/Day = Strength per Unit × (Number of units / Days supply) × MME conversion factor
| Morphine Milligram Equivalent (MME) | Naproxen Sodium | Hydrocodone / APAP | Placebo |
|---|---|---|---|
| Amount of Rescue Medication | 7.8 ± 3.08 | 9.3 ± 4.02 | 10.5 ± 4.50 |
If a subject did not take the rescue medication during the treatment period, (s)he was censored at the time of last assessment.
| Hours | Naproxen Sodium | Hydrocodone / APAP | Placebo |
|---|---|---|---|
| Time to First Use of Rescue Medication | NA (NA to NA) | 10.42 (8.27 to NA) | 2.57 (1.83 to 7.60) |
| Hours | Naproxen Sodium | Hydrocodone / APAP | Placebo |
|---|---|---|---|
| Duration of Pain at Least Half Gone Over 12 Hours | 8.87 ± 0.46 | 6.57 ± 0.46 | 3.31 ± 0.64 |
| Hours | Naproxen Sodium | Hydrocodone / APAP | Placebo |
|---|---|---|---|
| Duration of Pain at Least Half Gone Over 6 Hours | 4.60 ± 0.22 | 4.08 ± 0.22 | 1.49 ± 0.31 |
Collected over From first dose of the study drug administration until end of study treatment, up to 1 day. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naproxen Sodium | 0/90 (0%) | 0/90 (0%) | 2/90 (2.2%) |
| Hydrocodone/APAP | 0/87 (0%) | 0/87 (0%) | 33/87 (37.9%) |
| Placebo | 0/44 (0%) | 0/44 (0%) | 11/44 (25%) |
| Event | Naproxen Sodium | Hydrocodone/APAP | Placebo |
|---|---|---|---|
| Gastrointestinal disordersGastrointestinal disorders | 1/90 | 30/87 | 9/44 |
| Nervous system disordersNervous system disorders | 1/90 | 9/87 | 4/44 |
| General disorders and administration site conditionsGeneral disorders | 0/90 | 1/87 | 0/44 |
Safety Population: included all subjects who were randomized and received at least one dose of study drug
| Age, Continuous(Years) | Naproxen Sodium | Hydrocodone / APAP | Placebo | Total |
|---|---|---|---|---|
| Mean | 19.3 ± 1.62 | 19.3 ± 1.69 | 19.3 ± 2.00 | 19.3 ± 1.72 |
| Sex: Female, Male(Participants) | Naproxen Sodium | Hydrocodone / APAP | Placebo | Total |
|---|---|---|---|---|
| Female | 50 | 42 | 20 | 112 |
| Male | 40 | 45 | 24 | 109 |
| Ethnicity (NIH/OMB)(Participants) | Naproxen Sodium | Hydrocodone / APAP | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 18 | 18 | 6 | 42 |
| Not Hispanic or Latino | 72 | 69 | 38 | 179 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Baseline pain intensity(Participants) | Naproxen Sodium | Hydrocodone / APAP | Placebo | Total |
|---|---|---|---|---|
| Moderate | 34 | 36 | 17 | 87 |
| Severe | 56 | 51 | 27 | 134 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Ran from Mar 2020 to primary completion in Oct 2020, 6 months.
Results were first posted in Oct 2021, 1 year after primary completion.
Of 295 phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naproxen